ProAgio tagged posts

ProAgio, a drug developed by Georgia State University biology professor Zhi-Ren Liu and his team, is effective at treating pancreatic cancer and prolonging survival in mice, according to a study published in the journal Cellular and Molecular Gastroenterology and Hepatology.

A second study, published in the Journal of Experimental Medicine, shows the drug is also effective against triple-negative breast cancer, a fast-growing and hard-to-treat type of breast cancer that carries a poor prognosis.

ProAgio, created from a human protein, targets the cell surface receptor  integrin α_vβ₃ which is expressed on cancer-associated fibroblasts...

ProAgio induces apoptosis by recruiting caspase 8, that plays an essential role in programmed cell death, to the cytoplasmic area of integrin v3

A protein designed Georgia State Uni researchers can effectively target a cell surface receptor linked to a number of diseases, showing potential as a therapeutic treatment for an array of illnesses, including cancer. ProAgio, which is created from a human protein, targets the cell surface receptor integrin v3 at a novel site that has not been targeted by other scientists. The researchers found ProAgio induces apoptosis of cells that express integrin v3. This integrin has been a focus for drug development because abnormal expression of v3 is linked to the development and progression of a number of diseases.

“This integrin pair, v3, is not expresse...